Research proton and photon radiotherapy in stage III non-small cell lung cancer
Valuable news for lung cancer patients with stage III non-small-cell lung cancer. A rstudy led by Professor Dirk De Ruysscher, called ‘Proton and photon radiotherapy in stage III NSCLC: effects on haematological toxicity and adjuvant immunotherapy’, shows direct patient impact.
The study demonstrates for the first time the benefit of proton therapy, and this multicentre, in patients with locally extensive non-small cell lung carcinoma receiving concurrent chemotherapy and radiotherapy followed by immunotherapy. These patients are more likely to maintain good condition (13% regression with protons versus 26% with photons), require fewer blood transfusions (9% with protons versus 26% with photons) and they are more likely to receive immunotherapy (74% with protons versus 52% with photons) which may improve their long-term survival and/or cure.
These findings were presented by Professor Dirk De Ruysscher at a recent Holland PTC lustrum. Also, the study was recently published in the Green Journal.
More information
Read more about the publication, via: LinkedIn, Pubmed or the abstract from Radiotherapy and Oncology.